These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
551 related articles for article (PubMed ID: 15551293)
81. [Current national and international status of supportive therapy for the coagulopathy associated with L-asparaginase containing regimen for acute lymphoblastic leukemia]. Ogawa C; Manabe A; Ohara A; Ishiguro A Rinsho Ketsueki; 2013 Mar; 54(3):316-8. PubMed ID: 23676650 [TBL] [Abstract][Full Text] [Related]
82. Is asparaginase a critical component in the treatment of acute lymphoblastic leukemia? Douer D Best Pract Res Clin Haematol; 2008 Dec; 21(4):647-58. PubMed ID: 19041604 [TBL] [Abstract][Full Text] [Related]
83. L-asparaginase induced hypoglycemia in a case of acute lymphoblastic leukemia: a patient report. Misgar RA; Laway BA; Rahaman SH; Wani AI; Bashir MI; Bhat JR J Pediatr Endocrinol Metab; 2015 Mar; 28(3-4):439-41. PubMed ID: 25210761 [TBL] [Abstract][Full Text] [Related]
84. A genome-wide view of the in vitro response to l-asparaginase in acute lymphoblastic leukemia. Fine BM; Kaspers GJ; Ho M; Loonen AH; Boxer LM Cancer Res; 2005 Jan; 65(1):291-9. PubMed ID: 15665306 [TBL] [Abstract][Full Text] [Related]
85. Thrombophilia and cancer. Horowitz N; Brenner B Pathophysiol Haemost Thromb; 2008; 36(3-4):131-6. PubMed ID: 19176986 [TBL] [Abstract][Full Text] [Related]
86. An experience with plasma exchange treatment of acute lymphoblastic leukemia in a case with fulminant hepatitis related to L-asparaginase. Bilgir O; Calan M; Bilgir F; Cagliyan G; Arslan O Transfus Apher Sci; 2013 Oct; 49(2):328-30. PubMed ID: 23871581 [TBL] [Abstract][Full Text] [Related]
87. Intravascular coagulation phenomena associated with prevalent fall in fibrinogen and plasminogen during L-asparaginase treatment in leukemic children. Legnani C; Palareti G; Pession A; Poggi M; Vecchi V; Bianchini B; Coccheri S Haemostasis; 1988; 18(3):179-86. PubMed ID: 3181817 [TBL] [Abstract][Full Text] [Related]
88. Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study. Huguet F; Leguay T; Raffoux E; Thomas X; Beldjord K; Delabesse E; Chevallier P; Buzyn A; Delannoy A; Chalandon Y; Vernant JP; Lafage-Pochitaloff M; Chassevent A; Lhéritier V; Macintyre E; Béné MC; Ifrah N; Dombret H J Clin Oncol; 2009 Feb; 27(6):911-8. PubMed ID: 19124805 [TBL] [Abstract][Full Text] [Related]
89. L-asparaginase as a marker of chemotherapy dose modification in children with acute lymphoblastic leukemia. Baillargeon J; Langevin AM; Lewis M; Thomas PJ; Mullins J; Dugan J; Pollock BH Cancer; 2005 Dec; 104(12):2858-61. PubMed ID: 16288492 [TBL] [Abstract][Full Text] [Related]
90. [The feasibility of Erwinia asparaginase for pediatric patients who developed an allergic reaction to E.coli asparaginase during treatment of acute lymphoblastic leukemia]. Takahashi H; Koh K; Kato M; Isobe K; Yasui N; Mori M; Akiyama K; Kikuchi A; Hanada R Rinsho Ketsueki; 2013 Apr; 54(4):370-7. PubMed ID: 23666219 [TBL] [Abstract][Full Text] [Related]
91. Thrombosis related to the use of L-asparaginase in adults with acute lymphoblastic leukemia: a need to consider coagulation monitoring and clotting factor replacement. Alberts SR; Bretscher M; Wiltsie JC; O'Neill BP; Mokri B; Witzig TE Leuk Lymphoma; 1999 Feb; 32(5-6):489-96. PubMed ID: 10048421 [TBL] [Abstract][Full Text] [Related]
93. [Acquired deficiencies in antithrombin III and C protein during treatment with L-asparaginase]. Mielot F; Danel P; Boyer C; Coulombel L; Dommergues JP; Tchernia G; Larrieu MJ Arch Fr Pediatr; 1987 Mar; 44(3):161-5. PubMed ID: 2883953 [TBL] [Abstract][Full Text] [Related]
94. [L-asparaginase, antithrombin III deficiency and thromboses (author's transl)]. Bordigoni P; Briquel E; Olive D Arch Fr Pediatr; 1981 Nov; 38(9):653-5. PubMed ID: 6949499 [TBL] [Abstract][Full Text] [Related]
95. Prophylactic therapy with enoxaparin in children with acute lymphoblastic leukemia and inherited thrombophilia during L-asparaginase treatment. Harlev D; Zaidman I; Sarig G; Ben Arush MW; Brenner B; Elhasid R Thromb Res; 2010 Aug; 126(2):93-7. PubMed ID: 20546854 [TBL] [Abstract][Full Text] [Related]
96. Antithrombin III infusion suppresses the hypercoagulable state in adult acute lymphoblastic leukaemia patients treated with a low dose of Escherichia coli L-asparaginase. A GIMEMA study. Mazzucconi MG; Gugliotta L; Leone G; Dragoni F; Belmonte MM; De Stefano V; Chistolini A; Tura S; Mandelli F Blood Coagul Fibrinolysis; 1994 Feb; 5(1):23-8. PubMed ID: 7514043 [TBL] [Abstract][Full Text] [Related]
97. Changes of amino acid serum levels in pediatric patients with higher-risk acute lymphoblastic leukemia (CCG-1961). Grigoryan RS; Panosyan EH; Seibel NL; Gaynon PS; Avramis IA; Avramis VI In Vivo; 2004; 18(2):107-12. PubMed ID: 15113036 [TBL] [Abstract][Full Text] [Related]
98. Asparaginase-induced acute parotitis: an uncommon and self-limiting complication. Chan GC; Chiang AK; Ha SY; Lau YL; Ong JB; Lee AC Med Pediatr Oncol; 2002 Jul; 39(1):73-4. PubMed ID: 12116090 [No Abstract] [Full Text] [Related]
99. Inefficacy of fresh frozen plasma in the treatment of L-asparaginase-induced coagulation factor deficiencies during ALL induction therapy. Nowak-Göttl U; Rath B; Binder M; Hassel JU; Wolff J; Husemann S; Ritter J Haematologica; 1995; 80(5):451-3. PubMed ID: 8566890 [TBL] [Abstract][Full Text] [Related]
100. Toxicity Profile of PEG-Asparaginase in Adult Patients With Acute Lymphoblastic Leukemia in Brazil: A Multicenter Cross-Sectional Study. Silva WFD; Massaut IHB; Bendlin RM; Rosa LI; Velloso EDRP; Rego EM; Rocha V Clin Lymphoma Myeloma Leuk; 2020 Aug; 20(8):e523-e528. PubMed ID: 32389674 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]